CICC
Stellantis buys 20% stake in VC-backed Chinese EV maker
LeapMotor, a Chinese electric vehicle (EV) manufacturer that received substantial private funding prior to its Hong Kong IPO in September 2022, has agreed to sell an approximately 20% stake to European automaker Stellantis for HKD 8.5bn (USD 1.1bn).
PE-backed Concord Healthcare pursues HK IPO
Concord Healthcare Group, an onshore subsidiary of US-listed Chinese healthcare business Concord Medical, has filed for an IPO in Hong Kong.
CICC leads $60m Series B for China's Grit Biotechnology
CICC Capital had led a USD 60m Series B round for Grit Biotechnology, a Shanghai-based drug developer that is working on pioneering cancer treatments involving tumour-infiltrating lymphocytes (LIT).
Deal focus: National team drives Hithium towards China IPO
Government and state-owned investors accounted for most, but not all, of Xiamen Hithium Energy Storage Technology’s USD 622m Series C, underlining where China’s strategic priorities lie
Boyu leads Series C for China's Space Pioneer
Boyu Capital has led a Series C round amounting to several hundred million renminbi for Space Pioneer, a China-based aerospace company. CICC Capital and Youshan Capital also participated.
China's Hithium Energy Storage raises $622m
Xiamen Hithium Energy Storage Technology, a China-based battery manufacturer, has raised a Series C round of CNY 4.5bn (USD 622m) led by Beijing Financial Street Capital and China Life Insurance's private equity unit.
China e-commerce SaaS player files for Hong Kong IPO
Jushuitan, which claims to be China’s largest e-commerce software-as-a-service (SaaS) enterprise resource planning (ERP) provider, has filed for a Hong Kong IPO.
China electronics materials supplier raises $70m
China’s Fuyang Sineva Material Technology, a specialist in light-sensitive polymers called photoresists, has raised about CNY 500m (USD 70m) in Series D funding led by Peak View Capital.
CDH, Oriza-backed CSI Solar enjoys strong Star Market debut
CSI Solar, a Chinese renewables business backed by CDH Investments and Oriza Holdings, increased 18% in value on its first day of trading following a CNY 6bn (USD 840m) IPO.
China intelligent chassis supplier raises $58m
Global Technology, a China-based provider of intelligent chassis, has raised a Series C round of CNY 400m (USD 58m) from CICC Capital, Shenzhen Investment Holdings Capital, Qingyan Capital, and Huosen H&S.
China Life, Qianhai Ark back ophthalmic device maker
China Life Private Equity and Shenzhen-based Qianhai Ark have led a CNY 300m (USD 44m) Series C round for Svision Imaging, a China-based ophthalmic device manufacturer.
CDB leads $72m round for China RPA provider Kingsware
CDB Capital has led a CNY 500m (USD 72m) Series C round for Zhuhai-based robotic process automation (RPA) services provider Kingsware Information Technology.
Southeast Asia, China GPs bullish on exits in 2023
Investors targeting Southeast Asia and China told the Hong Kong Venture Capital & Privat Equity Association's (HKVCA) Asia forum that they were encouraged by liquidity events in 2022 and expect to see more exit opportunities this year.
Cloudview leads $221m round for China solar panel maker
China’s Cloudview Capital has led a CNY 1.5bn (USD 221m) Series B round for Astronergy, a solar panel manufacturer based in Zhejiang province.
Q&A: CICC Capital’s Mengyang Yang
Mengyang Yang, an executive director and head of private equity in Hong Kong at CICC Capital, on China’s post-pandemic revival, plans for a flagship US dollar fund, and managing guidance funds
2023 preview: China macro
Private equity is eager to re-engage with China as a sudden post-pandemic re-opening reminds investors focused on the country to expect the unexpected. A weak global picture could spoil the party
China CRO Safe Pharma gets $71m Series D
Safe Pharmaceutical Research Institute, a Beijing-based clinic research organization (CRO) focused on novel drugs, has raised a CNY500m (USD 71m) Series D round led by SDIC Venture Capital and China State-owned Venture Capital Fund.
China investors plan to step up activity – AVCJ Forum
Investors told the AVCJ Private Equity & Venture Forum that they are looking to accelerate their pace of investment in China next year despite economic and regulatory challenges.
China's Giant Biogene trades up after $70m Hong Kong IPO
Giant Biogene, a China-based producer of skin treatments that use bioactive ingredients, gained nearly 10% on debut following a HKD 549.4m (USD 70m) Hong Kong IPO.
China EV player Leapmotor targets Hong Kong IPO
LeapMotor has filed for an IPO in Hong Kong, putting it on course to become the fourth of China's "new force" electric vehicle (EV) manufacturers to go public.
China trucking fleet platform Duckbill raises $49m
China’s Duckbill, a fleet management platform for the trucking industry, has raised CNY 330m (USD 49m) in a Series C round led by CICC Capital.
AstraZeneca-CICC fund backs China gene sequencer
Axbio, a China-based provider of gene sequencing and diagnostic systems, has raised nearly USD 100m in Series B funding led by AstraZeneca-CICC Healthcare Industrial Fund and Yunfeng Capital.
China virotherapy specialist Binhui Biopharm raises $47m
Binhui Biopharm, a Chinese biotech firm specialising in oncolytic virus immune-oncology, has raised CNY 300m (USD 47m) in an extended Series B round led by Yangtze River Pharmaceutical Group.
China 3D cell culture business secures Series B
CytoNiche, a Beijing-based provider of 3D micro-structure engineering technology used for stem cell research, has raised nearly CNY 300m (USD 47m) in a Series B led by Gaorong Capital and CICC Capital.